| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Vertex Pharmaceuticals Inc‘s (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, potentially extending the lives of some patients by up to 45 years.
Despite its high cost of $300,000 per patient annually in the U.S., sales remain robust.
Since its launch in 2019, Trikafta has amassed $26 billion in revenues and is expected to reach $10 billion in annual sales next year.
Additionally, Vertex anticipates regulatory approval for its fifth CF treatment, the vanza triple, this year, with projected annual sales matching Trikafta’s success.
The Financial Times cites a Guggenheim Securities analyst and writes that Vertex is poised for substantial growth and will emerge as a top contender among pharmaceutical companies.
Daniel Lyons, a portfolio manager at Janus Henderson, highlights Vertex’s dominant position in CF treatment. Patent protection extends until at least 2039, providing a solid foundation for sustained profitability and continued research investments.
Now, the same research team at Vertex’s San Diego lab is nearing the culmination of another extensive project: developing non-opioid painkillers, presenting a new avenue for substantial market expansion.
Vertex’s challenge lies in replicating its success in cystic fibrosis (CF) treatment across other diseases.
Recently, it gained regulatory approval for a groundbreaking CRISPR gene editing-based therapy for sickle cell disease and beta-thalassemia.
Moreover, Vertex acquired Alpine Immune Sciences Inc (NASDAQ:ALPN) for $4.9 billion, a move aimed at developing a treatment for autoimmune kidney disease.
However, analysts highlight a new generation of non-addictive painkillers as the most promising in Vertex’s pipeline.
VX-548, a non-opioid painkiller, is undergoing late-stage clinical trials and shows potential for FDA approval this year.
It promises reduced pain with fewer side effects and no risk of addiction compared to traditional opioids.
The Financial Times highlights that analysts predict that Vertex’s new acute pain medication will bring in $2.3 billion in yearly sales by 2030. However, the real potential lies in their approved non-opioid painkiller, offering an alternative to prescription opioids.
Price Action: VRTX shares are up 0.08% at $398.02 at the last check Friday.
